Concomitant inhibition of Bcl-xL and Mcl-1 expression by RNA interference as a novel strategy for the treatment of ovarian carcinomas

被引：0

作者：

Denoyelle, C. ^{[1
]}

Brotin, E. ^{[1
]}

Duval, R. ^{[1
]}

Simonin, K. ^{[1
]}

Meryet-Figuiere, M. ^{[1
]}

N'Diaye, M. ^{[1
]}

Louis, M. H. ^{[1
]}

Dutoit, S. ^{[1
]}

Gauduchon, P. ^{[1
]}

Poulain, L. ^{[1
]}

机构：

[1] Ctr Francois Baclesse, F-14021 Caen, France

来源：

EJC SUPPLEMENTS | 2008年 / 6卷 / 09期

关键词：

D O I：

10.1016/S1359-6349(08)71490-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：81 / 82

页数：2

共 50 条

[31] mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Faber, Anthony C.
Coffee, Erin M.
Costa, Carlotta
Dastur, Anahita
Ebi, Hiromichi
Hata, Aaron N.
Yeo, Alan T.
Edelman, Elena J.
Song, Youngchul
Tam, Ah Ting
Boisvert, Jessica L.
Milano, Randy J.
Roper, Jatin
Kodack, David P.
Jain, Rakesh K.
Corcoran, Ryan B.
Rivera, Miguel N.
Ramaswamy, Sridhar
Hung, Kenneth E.
Benes, Cyril H.
Engelman, Jeffrey A.
CANCER DISCOVERY, 2014, 4 (01) : 42 - 52
[32] A computational perspective for tailor-made selective Mcl-1 and Bcl-XL inhibitors
Huang, Danxia
Wang, Ying
Hu, Baichun
Luo, Zhaohu
Huang, Junhao
Wang, Jian
Zhang, Fengjiao
JOURNAL OF MOLECULAR STRUCTURE, 2022, 1253
[33] RNA interference-based strategies directed against Bcl-xL and MCL1 for the treatment of malignant pleural mesothelioma
Varin, E.
Denoyelle, C.
Brotin, E.
Lemoisson, E.
Giffard, F.
Icard, P.
Poulain, L.
EJC SUPPLEMENTS, 2008, 6 (09): : 82 - 82
[34] Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
Kim, Seonghoon
Park, Hee-Sung
Oh, Byung-Ha
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 3019 - 3029
[35] Synthesis of a rhodanine-based compound library targeting Bcl-XL and Mcl-1
Bernardo, Paul H.
Sivaraman, Thirunavukkarasu
Wan, Kah-Fei
Xu, Jin
Krishnamoorthy, Janarthanan
Song, Chun Meng
Tian, Liming
Chin, Jasmine S. F.
Lim, Diane S. W.
Mok, Henry Y. K.
Yu, Victor C.
Tong, Joo Chuan
Chai, Christina L. L.
PURE AND APPLIED CHEMISTRY, 2011, 83 (03) : 723 - 731
[36] BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F. Lee
Tiffany J. Harris
Sharon Tran
Marco Evangelista
Surein Arulananda
Thomas John
Celeste Ramnac
Chloe Hobbs
Haoran Zhu
Gency Gunasingh
David Segal
Andreas Behren
Jonathan Cebon
Alexander Dobrovic
John M. Mariadason
Andreas Strasser
Leona Rohrbeck
Nikolas K. Haass
Marco J. Herold
W. Douglas Fairlie
Cell Death & Disease, 10
[37] A computational perspective for tailor-made selective Mcl-1 and Bcl-XL inhibitors
Huang, Danxia
Wang, Ying
Hu, Baichun
Luo, Zhaohu
Huang, Junhao
Wang, Jian
Zhang, Fengjiao
JOURNAL OF MOLECULAR STRUCTURE, 2022, 1253
[38] BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Lee, Erinna F.
Harris, Tiffany J.
Tran, Sharon
Evangelista, Marco
Arulananda, Surein
John, Thomas
Ramnac, Celeste
Hobbs, Chloe
Zhu, Haoran
Gunasingh, Gency
Segal, David
Behren, Andreas
Cebon, Jonathan
Dobrovic, Alexander
Mariadason, John M.
Strasser, Andreas
Rohrbeck, Leona
Haass, Nikolas K.
Herold, Marco J.
Fairlie, W. Douglas
CELL DEATH & DISEASE, 2019, 10
[39] GCS-100: A novel therapy for myeloma inhibits Mcl-1, bcl-xL and cell cycle proteins
Streetly, M. J.
Su, B.
Schey, S. A.
Kazmi, M.
Cotter, F. E.
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 1 - 2
[40] Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Melvold, Katrine
Giliberto, Mariaserena
Karlsen, Linda
Ayuda-Duran, Pilar
Hanes, Robert
Holien, Toril
Enserink, Jorrit
Brown, Jennifer R.
Tjonnfjord, Geir E.
Tasken, Kjetil
Skanland, Sigrid S.
MOLECULAR ONCOLOGY, 2022, 16 (05) : 1153 - 1170

← 1 2 3 4 5 →